Semaglutide vs Metformin in polycystic ovary syndrome (PCOS)
Research type
Research Study
Full title
The effect of Semaglutide compared to metformin in obese women with polycystic ovary syndrome (PCOS): a randomised controlled trial (Semaglutide-PCOS study-SEMMET).
IRAS ID
280123
Contact name
Thozhukat Sathyapalan
Contact email
Sponsor organisation
Research and development, Hull University Teaching Hospital NHS trust
Eudract number
2021-001361-20
Duration of Study in the UK
0 years, 5 months, 1 days
Research summary
Polycystic ovary syndrome (PCOS) is a very common condition in women of reproductive age. PCOS may present with irregular periods, excessive hair growth on the face and body, acne and cysts in the ovaries. PCOS is also associated with an increased risk of problems later in life like diabetes, high cholesterol levels and heart disease.
In this trial, a medicine called semaglutide will be tested. Semaglutide belongs to a class of medications called Glucagon like-peptide 1 (GLP-1). This medicine will stimulate insulin release from the pancreas, slow the movement of food through the stomach so it makes you feel full. Semaglutide is usually used in type 2 diabetes and has led to improved blood glucose levels and weight loss. The plan is to give semaglutide to women with PCOS to see its effect on metabolic, hormonal parameters and quality of life . This will be compared with metformin (drug for diabetes) which has been used in PCOS with very good results.REC name
London - Brent Research Ethics Committee
REC reference
22/LO/0221
Date of REC Opinion
3 May 2022
REC opinion
Further Information Favourable Opinion